Bardoxolone (methyl) Size:Solid 2 mg caspase-mediated pathway

caspase-mediated pathway

4-hydroxytamoxifen

InChiKey: DXVKFBGVVRSOLI-UHFFFAOYSA-N

InChi: InChI=1S/C49H78N6O10/c1-13-32(6)44(37(64-11)29-41(59)54-28-20-23-36(54)46(65-12)33(7)47(61)50-34(8)45(60)35-21-16-14-17-22-35)53(10)49(63)42(30(2)3)51-48(62)43(31(4)5)52(9)38(56)24-18-15-19-27-55-39(57)25-26-40(55)58/h14

and tumor cell growth in susceptible tumor cell populations

Bardoxolone (methyl) Size:Solid 2 mg caspase-mediated pathwayBardoxolone methyl (also known as RTA 402 and CDDO methyl ester) is an orally available first in class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation. Bardoxolone methyl is currently being developed by Reata Pharmaceuticals, Inc. in partnership with Abbott